|
By Michael Quigley, Director of Research, LSN
 On Monday, August 18, LSN's partnering system for our Redefining Early Stage Investments (RESI) Conference will go live. The purpose of the system is to help scientist-entrepreneurs and funding executives connect at the conference with potential investors.
Using the LSN's partnering system is fairly straightforward. Registered scientists and executives enter information about their company's research-including technology type, indication, and phase of development-and the system identifies registered investors who may be a fit. Then scientists and executives use the system to book meetings-as many as 16 per attendee-with those investors... |
|
 LSN Globally tracks technology platforms and has been able to yield some interesting data by classifying the different platform types and assessing the number of technologies within each classification. As you can see in Exhibit 1 LSN breaks down technology platforms into 26 categories as described below:..
|
 In today's fundraising environment, investors are inundated, sometimes seeing hundreds of executive summaries a month. Life science entrepreneurs, on the other hand, are all but obligated to run a calculated outbound sales and marketing campaign. But how do you set yourself apart from the crowd? This panel features successful life science entrepreneurs at various stages of their fundraising campaigns, telling their tales from the road.
Moderated by Rick Berenson, CEO of Thermalin Diabetes, the audience will hear from:
- Fred Colen, President & CEO, BeneChill
- Richard Gauthier, Head of Business Development, Microbiotix
- Gabor Bethlendy, CCO & Founder, Parabase Genomics
- Michael Tippie, CEO, TomegaVax
|
Life Science Investor Mandates 
